Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on July 20, 2023. The filing primarily addresses two significant legal matters: an update regarding pending litigation and a potential settlement with Sorrento Therapeutics, Inc., and the commencement of a putative securities class action lawsuit.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or margins. Regarding the Sorrento litigation, the Company states that as of June 30, 2023, it has not determined the amount it is likely to recover and has not recorded any receivables related to the judgments. No specific debt or liquidity figures are provided in this document.
Material Changes and Legal Developments
- Sorrento Therapeutics Litigation: A settlement motion is pending before the U.S. Bankruptcy Court for the Southern District of Texas, with a hearing scheduled for August 14, 2023. The settlement outlines two scenarios:
- If Sorrento raises funds to pay its creditors by August 31, 2023, it will pay obligations including judgments held by ImmunityBio's subsidiary NantCell, Inc., allowing pending litigation to proceed.
- If Sorrento fails to raise funds, judgments will be released, litigation claims (including derivative litigation) will be released, and Sorrento will relinquish interests in the NANTibody joint venture and rights to payments from NantCell.
- Securities Class Action: On June 30, 2023, a complaint was filed in the U.S. District Court for the Southern District of California (Salzman v. ImmunityBio, Inc. et al.). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act stemming from the Company's May 11, 2023 disclosure of an FDA complete response letter regarding its product candidate Anktiva (N-803). The complaint alleges false or misleading statements regarding third-party contract manufacturing organizations.
Outlook, Risks, and Management Commentary
Management intends to defend the securities class action vigorously, believing the lawsuit is without merit. However, the Company cannot estimate a range of loss for either the Sorrento litigation (if the settlement is not approved) or the securities class action. The filing includes extensive forward-looking statements warning of risks related to litigation outcomes, regulatory reviews, manufacturing capabilities, and the ability to secure financing. There is no assurance that the Sorrento settlement will be approved by the bankruptcy court.
Investor Verification Checklist
- Verify the outcome of the Sorrento Therapeutics settlement hearing scheduled for August 14, 2023.
- Monitor the status of the securities class action filed on June 30, 2023, and any subsequent motions or rulings.
- Review the Company's ability to address the FDA's complete response letter regarding Anktiva (N-803) and its impact on future commercialization.
- Assess the Company's liquidity position and ability to fund operations given the uncertainties surrounding potential litigation recoveries and ongoing development costs.